# Stereotaxis, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Stereotaxis, Inc.). ## Overview Stereotaxis designs and sells robotic magnetic navigation systems used in minimally invasive cardiac and endovascular procedures. Its portfolio includes capital systems, disposable interventional devices, software, imaging and workflow tools, and service offerings sold primarily to hospitals and physicians in the United States, Europe, and other international markets. ## Products & services • Robotic magnetic navigation systems • Disposable interventional devices and catheters • Imaging, workflow, and navigation software • Service, maintenance, and software updates • Diagnostic catheters (Map-iT) • Royalty and co-development arrangements - **Robotic magnetic navigation systems** (35%) — Capital equipment used to remotely navigate catheters in electrophysiology and related procedures. - **Disposable interventional devices** (30%) — Single-use catheters and related devices used during ablation and other procedures. - **Service and software** (20%) — Maintenance plans, service-type warranties, and software enhancements for installed systems. - **Diagnostic catheters** (10%) — Map-iT branded diagnostic catheters acquired through APT and used in cardiac ablation procedures. - **Royalties and other recurring revenue** (5%) — Royalties and other recurring revenue from co-development, co-placement, and related arrangements. - Robotic magnetic navigation systems - Disposable interventional devices and catheters - Imaging, workflow, and navigation software - Service, maintenance, and software updates - Diagnostic catheters (Map-iT) - Royalty and co-development arrangements ## Customers Stereotaxis sells primarily to hospitals, electrophysiology labs, and physicians performing cardiac ablation and other minimally invasive procedures. Its products are used by clinical teams that need robotic catheter control, imaging integration, and disposable devices for complex interventions. The company also works through distributors and sales agents in some markets, which broadens access beyond its direct sales force. - **Hospitals and electrophysiology labs** (primary) — Buy robotic magnetic navigation systems and related infrastructure for cardiac ablation programs. - **Electrophysiologists and interventional physicians** (primary) — Use disposable catheters, diagnostic devices, and software during procedures and drive clinical adoption. - **International distributors and agents** (secondary) — Purchase or resell products in markets where the company uses indirect channels to expand reach. - **Installed-base service customers** (secondary) — Buy maintenance plans, service-type warranties, and software updates for existing systems. - Hospitals and cardiac centers buying robotic EP systems - Electrophysiologists using catheters for ablation procedures - Clinical labs needing navigation, imaging, and workflow tools - Distributors and sales agents in selected international markets - Physician thought leaders who influence adoption and training ## Geography Stereotaxis markets its products in the U.S., Europe, and the rest of the world through direct sales and channel partners. The business is geographically important because system placements, regulatory approvals, and clinical adoption can vary significantly by region, affecting where the installed base and recurring device demand develop. Its APT catheter manufacturing footprint is based in Rogers, Minnesota, while corporate headquarters are in St. Louis, Missouri. - United States is the core market and headquarters location - Europe is a key market for robotic EP and catheter sales - Rest of world sales are supported by distributors and agents - APT catheter manufacturing is based in Rogers, Minnesota - Geographic expansion depends on regulatory approvals and adoption ## Strategy Stereotaxis is focused on expanding the installed base of robotic magnetic navigation systems and increasing utilization through disposable devices, software, and service. It is also developing additional interventional devices and broader clinical applications beyond electrophysiology, while using physician advocates and partnerships to support adoption. The APT acquisition adds in-house catheter development and manufacturing capability that supports this product expansion strategy. - **Increase adoption of robotic magnetic navigation systems** (short-term) — The installed base drives follow-on disposable, service, and software revenue. - **Expand proprietary disposable device portfolio** (medium-term) — Recurring device sales improve procedure-level monetization and customer stickiness. - **Broaden clinical applications beyond electrophysiology** (long-term) — New endovascular use cases can enlarge the addressable market for robotic navigation. - **Strengthen in-house manufacturing and development** (medium-term) — Internal capability can improve control over product design, supply, and innovation. - Expand robotic system placements and installed base utilization - Grow recurring revenue from disposables, service, and software - Develop new interventional devices for robotic navigation - Broaden use cases beyond electrophysiology into endovascular procedures - Use physician thought leaders and partnerships to drive adoption - Add internal catheter design and manufacturing capability ## Risks The business depends on regulatory approvals, clinical adoption, and successful conversion of backlog into revenue, all of which can be slow and uncertain in medical devices. It also faces competition from robotic navigation, imaging, and traditional catheter companies, while sales execution depends on access to hospitals, physician support, and distributor performance. Because products are sold into regulated procedures, revenue recognition, inventory, warranty, and acquisition-related estimates can materially affect reported results. - **Regulatory approval delays** [high] — New disposable devices and system features require clearance before commercialization. - **Clinical adoption risk** [high] — Hospitals and physicians may be slow to adopt robotic workflows or switch from conventional tools. - **Competitive pressure** [medium] — The company competes with established device makers and robotic navigation developers. - **Sales force and distributor execution** [medium] — Revenue depends on access, training, and effective channel management across regions. - **Acquisition integration** [medium] — APT must be integrated into operations, quality systems, and product development plans. - Regulatory approval timing can delay product launches and adoption - Hospital and physician adoption can be slow and difficult to predict - Competition from robotic, imaging, and traditional catheter companies - Sales execution depends on direct reps, distributors, and clinical support - Acquisition integration and product development execution risk ## Accounting Revenue is recognized across several models, including capital system sales, disposable devices, royalties, and service/software arrangements, so timing depends on contract terms and performance obligations. Deferred revenue, contract assets, customer deposits, warranty estimates, and capitalized sales incentives can all move reported results between periods, while the APT acquisition adds goodwill and intangible asset impairment considerations. Because some revenue is tied to system placements and service periods, quarter-to-quarter comparisons can be affected by mix and billing schedules. - **Revenue recognition by contract type** — Reported revenue and gross margin can shift with product mix and billing terms - **Deferred revenue and contract assets** — Quarterly revenue and balance sheet working capital - **Warranty and installation estimates** — Cost of revenue and gross margin - **Goodwill and intangible assets** — Non-cash impairment charges if expected benefits do not materialize - **Capitalized sales incentives** — Operating expense timing and asset balances - ASC 606 timing differs for systems, disposables, royalties, and services - Deferred revenue affects when service and software revenue is recognized - Contract assets and customer deposits reflect billing vs performance timing - Warranty and installation estimates affect cost of revenue - Goodwill and intangibles from APT require impairment testing --- *Last updated: 2026-04-29T05:00:19.490944+00:00*